The capacity of NK cells to destroy GBM cells when triggered by IL‐2,72 as well as their efficiency in preventing metastasis in a GBM xenograft mouse model,73 have all been demonstrated in preclinical models of GBM.72 This evidence concerns the gene IL2 and glioblastoma.